Ocugen (NASDAQ:OCGN) Director Junge Zhang Buys 270,000 Shares of Stock

Ocugen (NASDAQ:OCGN) Director Junge Zhang purchased 270,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were purchased at an average price of $0.37 per share, for a total transaction of $99,900.00. Following the acquisition, the director now directly owns 600,078 shares of the company’s stock, valued at $222,028.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Junge Zhang also recently made the following trade(s):

  • On Monday, November 25th, Junge Zhang purchased 115,000 shares of Ocugen stock. The shares were purchased at an average price of $0.27 per share, for a total transaction of $31,050.00.
  • On Friday, November 22nd, Junge Zhang purchased 80,000 shares of Ocugen stock. The shares were purchased at an average price of $0.28 per share, for a total transaction of $22,400.00.
  • On Monday, November 18th, Junge Zhang purchased 100,000 shares of Ocugen stock. The shares were purchased at an average price of $0.41 per share, for a total transaction of $41,000.00.
  • On Friday, October 11th, Junge Zhang purchased 4,000 shares of Ocugen stock. The shares were purchased at an average price of $1.82 per share, for a total transaction of $7,280.00.
  • On Monday, September 30th, Junge Zhang purchased 31,078 shares of Ocugen stock. The shares were purchased at an average price of $3.09 per share, for a total transaction of $96,031.02.

Shares of OCGN opened at $0.42 on Tuesday. The company’s 50 day moving average is $1.13. Ocugen has a 52 week low of $0.23 and a 52 week high of $34.80.

Ocugen (NASDAQ:OCGN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.66) EPS for the quarter.

OCGN has been the topic of a number of recent analyst reports. Chardan Capital initiated coverage on shares of Ocugen in a report on Wednesday, November 27th. They set a “buy” rating and a $2.00 price target on the stock. ValuEngine upgraded shares of Ocugen from a “hold” rating to a “buy” rating in a report on Friday, November 1st.

Ocugen Company Profile

Ocugen, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases.

See Also: Book Value Per Share in Stock Trading

Insider Buying and Selling by Quarter for Ocugen (NASDAQ:OCGN)

Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.